Triple-negative breast cancer possibly transforming into malignant melanoma due to targeted therapy? A case report and review of literature

被引：1

作者：

Aigner B. ^{[1
]}

Plötz S.G. ^{[2
]}

Schaller G. ^{[3
]}

机构：

[1] Department for Dermatology, Medical University of Graz, 8036 Graz

[2] Dermatology Munich-Harlaching, 81545 Munich

[3] Breast Care Institute Munich, 80796 München

来源：

Wiener Medizinische Wochenschrift | 2013年 / 163卷 / 21-22期

关键词：

Breast cancer; Malignant melanoma; Targeted therapy; Triple-negative disease;

D O I：

10.1007/s10354-013-0242-0

中图分类号：

学科分类号：

摘要：

Summary: Background: Triple-negative breast cancer (TNBC) is characterized by lacking expression of estrogen receptor and progesterone receptor as well as absence of human epidermal growth factor receptor 2 overexpression and is an aggressive clinical phenotype. Patients and methods: We report the case of a 33-year-old woman who has been treated using a targeted approach for TNBC and developed a malignant melanoma metastasis without any primary. Results and conclusion: Using targeted therapies, tumors can be treated much more effectively, but up to now, we do not know much about potential adverse reactions. Due to the targeted therapy, tumors may be pressurized for transformation. We call for further investigations to rule out the potential risks of targeted therapy in TNBC. This is the first report of a potential transforming of one tumor entity to another by a targeted therapy. © 2013 Springer-Verlag Wien.

引用

页码：495 / 498

页数：3

共 16 条

[1]

Berrada N., Delaloge S., Andre F., Treatment of triple-negative metastatic breast cancer: Toward individualized targeted treatments or chemosensitization?, Ann Oncol, 21, 7, pp. 30-35, (2010)

[2]

Pal S.K., Childs B.H., Pegram M., Triple negative breast cancer: Unmet medical needs, Breast Cancer Res Treat., 125, pp. 627-636, (2011)

[3]

Carey L.A., Perou C.M., Livasy C.A., Race, breast cancer subtypes and survival in the Carolina breast cancer study, JAMA, 295, pp. 2492-2502, (2006)

[4]

Alvarez R.H., Valero V., Hortobagyi G.N., Emerging targeted therapies for breast cancer, J Clin Oncol, 28, pp. 3366-3379, (2010)

[5]

Andre F., Job B., Dessen P., Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array, Clin Cancer Res, 14, pp. 441-451, (2009)

[6]

Buhler H., Schaller G., Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo, Mol Cancer Res, 3, 7, pp. 356-371, (2005)

[7]

Sikov W.M., Dizon D.S., Strenger R., Frequent pathological complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: A Brown University Oncology Group Study, J Clin Oncol, 27, 28, pp. 4693-4700, (2009)

[8]

Loesch D., Robert N., Asmar L., Phase II multicentre trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer, J Clin Oncol., 20, 18, pp. 3857-3864, (2002)

[9]

Chang H.R., Glaspy J., Allison M.A., Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment, Cancer., 116, pp. 4227-4237, (2010)

[10]

Gray R., Bhattacharya S., Bowden C., Independent review of E2100: A phase III trail of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer, J Clin Oncol., 27, pp. 4966-4972, (2009)

← 1 2 →